经林业发展局批准的药物bupivacaine和rimegepant通过阻塞疼痛和肿瘤支持蛋白质,减缓了小鼠骨癌的生长速度,显示出治疗人类的希望。 FDA-approved drugs bupivacaine and rimegepant slowed bone cancer growth in mice by blocking pain and tumor-supporting proteins, showing promise for human treatment.

由约翰·霍普金斯主导的一项研究发现,由林业发展局批准的两种药物——bupivacaine和rimegepant——能够阻塞神经信号蛋白质CGRP、TrkA和NGF,从而延缓小鼠的骨癌(骨肉瘤)的生长,这些蛋白质支持肿瘤的进化和疼痛。 A Johns Hopkins-led study found that two FDA-approved drugs—bupivacaine and rimegepant—can slow bone cancer (osteosarcoma) growth in mice by blocking nerve signaling proteins CGRP, TrkA, and NGF, which support tumor progression and pain. 这些药物减少了肿瘤中神经和血管的形成,延长了存活期,减少了免疫障碍细胞。 The drugs reduced nerve and blood vessel formation in tumors, extended survival, and decreased immune-evading cells. 人类肿瘤样本显示了类似的蛋白质活动,表明有可能重新利用这些药物来治疗骨质瘤和缓解疼痛,尽管还需要进一步的临床试验。 Human tumor samples showed similar protein activity, suggesting potential for repurposing these drugs to treat osteosarcoma and relieve pain, though further clinical trials are needed.